Subscribe: Market Wire - Professional Services: Investor Relations
http://img.marketwire.com/rss/mwPSIR.rss
Preview: Market Wire - Professional Services: Investor Relations

Marketwired - Investor Relations



Marketwired - Investor Relations



Last Build Date: Fri, 16 Feb 2018 08:33:45 EST

Copyright: Copyright: (C) Marketwired
 



Top Line Results From Aironite Phase 2 Clinical Trial for the Treatment of HFpEF to Be Presented at American College of Cardiology 67th Annual Scientific Sessions & Expo on March 11th

Fri, 16 Feb 2018 08:00:00 EST

AUSTIN, TX--(Marketwired - February 16, 2018) - Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today reported that top line results from the multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial of Aironite, a sodium nitrite solution for inhalation via nebulization, in patients with heart failure with preserved ejection fraction (HFpEF) will be presented at the American College of Cardiology 67th Annual Scientific Sessions & Expo, to be held at the Orange County Convention Center in Orlando, Florida March 10-12, 2018.